Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04657224 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 75 | Janssen Research & Development, LLCINDUSTRY | 12 | Aug 21, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06978088 | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | recruiting | Phase 2 | 34 | Zulfa OmerOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 12 | Acerta Pharma BVINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07113132 | Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia | not yet recruiting | — | 84 | Safaa AliOTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | recruiting | Phase 1 | 36 | University Hospital TuebingenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02793544 | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | completed | Phase 2 | 80 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04159779 | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | active not recruiting | — | 180 | AbbVieINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | not yet recruiting | Phase 2 | 75 | British Columbia Cancer AgencyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT01290302 | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | completed | Phase 1 | 38 | American Regent, Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | completed | Phase 1 | 34 | Jennifer WoyachOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2025 | clinicaltrials |
| NCT07003464 | Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia(CORONADO CLL) | terminated | Phase 1 / Phase 2 | 5 | University of UtahOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | terminated | Phase 2 | 2 | University of MiamiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 53 | Northwestern UniversityOTHER | 2 | May 23, 2025 | clinicaltrials |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | withdrawn | Phase 2 | 0 | Inhye AhnOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT04938141 | MEOI and HRQoL in CLL Patients Treated With BTKis | completed | — | 23 | AstraZenecaINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | terminated | Phase 1 | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04578600 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | completed | Phase 1 | 8 | Joseph TuscanoOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06250465 | AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry | recruiting | — | 500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT06396611 | Exercise As Intervention in Chronic Lymphocytic Leukemia(ADRENALINE) | active not recruiting | N/A | 11 | Universidade do PortoOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04178798 | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 22 | PETHEMA FoundationOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04867915 | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | recruiting | — | 12,500 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2025source: clinicaltrials